335 related articles for article (PubMed ID: 24736543)
21. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
[TBL] [Abstract][Full Text] [Related]
22. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
23. Significant correlation between urinary N(1), N(12)-diacetylspermine and tumor invasiveness in patients with clinical stage IA non-small cell lung cancer.
Takahashi Y; Horio H; Sakaguchi K; Hiramatsu K; Kawakita M
BMC Cancer; 2015 Feb; 15():65. PubMed ID: 25884987
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
Cui D; Yu CH; Liu M; Xia QQ; Zhang YF; Jiang WL
Tumour Biol; 2016 Mar; 37(3):4127-34. PubMed ID: 26490983
[TBL] [Abstract][Full Text] [Related]
25. Glycine decarboxylase and HIF-1α expression are negative prognostic factors in primary resected early-stage non-small cell lung cancer.
Berezowska S; Galván JA; Langer R; Bubendorf L; Savic S; Gugger M; Schmid RA; Marti TM
Virchows Arch; 2017 Mar; 470(3):323-330. PubMed ID: 28062918
[TBL] [Abstract][Full Text] [Related]
26. Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients.
Li F; Huang J; Ji D; Meng Q; Wang C; Chen S; Wang X; Zhu Z; Jiang C; Shi Y; Liu S; Li C
Clin Transl Oncol; 2017 Oct; 19(10):1283-1291. PubMed ID: 28497422
[TBL] [Abstract][Full Text] [Related]
27. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
[No Abstract] [Full Text] [Related]
28. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
[TBL] [Abstract][Full Text] [Related]
29. Identification of miR‑124a as a novel diagnostic and prognostic biomarker in non‑small cell lung cancer for chemotherapy.
Luo P; Yang Q; Cong LL; Wang XF; Li YS; Zhong XM; Xie RT; Jia CY; Yang HQ; Li WP; Cong XL; Xia Q; Fu D; Zeng QH; Ma YS
Mol Med Rep; 2017 Jul; 16(1):238-246. PubMed ID: 28534972
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
[TBL] [Abstract][Full Text] [Related]
31. High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer.
Choi IK; Kim YH; Kim JS; Seo JH
Acta Oncol; 2010 Aug; 49(6):861-4. PubMed ID: 20553098
[No Abstract] [Full Text] [Related]
32. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.
Chen S; Zhao J; Cui L; Liu Y
Clin Transl Oncol; 2017 Mar; 19(3):332-340. PubMed ID: 27468867
[TBL] [Abstract][Full Text] [Related]
33. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.
Su K; Zhang T; Wang Y; Hao G
World J Surg Oncol; 2016 Aug; 14(1):224. PubMed ID: 27733164
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic investigation of BIRC6 and SIRT1 protein expression level as potential prognostic biomarkers in patients with non-small cell lung cancer.
Gharabaghi MA
Clin Respir J; 2018 Feb; 12(2):633-638. PubMed ID: 27768839
[TBL] [Abstract][Full Text] [Related]
37. High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis.
Qi SA; Wu Q; Chen Z; Zhang W; Zhou Y; Mao K; Li J; Li Y; Chen J; Huang Y; Huang Y
Sci Rep; 2021 Jun; 11(1):11805. PubMed ID: 34083687
[TBL] [Abstract][Full Text] [Related]
38. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
39. Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance.
Millares L; Barreiro E; Cortes R; Martinez-Romero A; Balcells C; Cascante M; Enguita AB; Alvarez C; Rami-Porta R; Sánchez de Cos J; Seijo L; Monsó E;
Lung Cancer; 2018 Aug; 122():124-130. PubMed ID: 30032820
[TBL] [Abstract][Full Text] [Related]
40. LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.
Zhou M; Kong Y; Wang X; Li W; Chen S; Wang L; Wang C; Zhang Q
Biomed Res Int; 2021; 2021():5561569. PubMed ID: 33728331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
